MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- CADILA HEALTHCARE LIMITED (pharmaceuticals)
- CADILA HEALTHCARE LIMITED Financial Data
Cadila Healthcare Fact Sheet (CADIL)
Going Live Today at 6PM: Know what opportunities India's growth story can create for you and more
Here is the latest financial fact sheet of Cadila Healthcare. For more details, see the Cadila Healthcare quarterly results and Cadila Healthcare share price and chart. For a sector overview, read our pharmaceuticals sector report.
CADILA HEALTHCARE Price History
| % ch | % | 4.4 |
| No. of shares | m | 1,023.74 |
| % ch week | % | 18.0 |
| % ch 1-mth | % | 33.6 |
| % ch 12-mth | % | 73.2 |
| 52 week H/L | Rs | 573.4/318.1 |
CADILA HEALTHCARE Financials
| No. of Mths Year Ending |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
5-Yr Chart Click to enlarge
|
|---|
| CADILA HEALTHCARE EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 454 | 460 | 558 | 432 | 352 | |
| Low | Rs | 305 | 305 | 362 | 306 | 207 | |
| Sales per share (Unadj.) | Rs | 92.1 | 91.6 | 116.3 | 128.6 | 139.2 | |
| Earnings per share (Unadj.) | Rs | 19.2 | 14.8 | 17.9 | 18.5 | 11.8 | |
| Diluted earnings per share | Rs | 19.2 | 14.8 | 17.9 | 18.5 | 11.8 | |
| Cash flow per share (Unadj.) | Rs | 22.0 | 18.5 | 23.1 | 24.4 | 18.6 | |
| Dividends per share (Unadj.) | Rs | 3.20 | 3.20 | 3.50 | 3.50 | 3.50 | |
| Adj. dividends per share | Rs | 3.20 | 3.20 | 3.50 | 3.50 | 3.50 | |
| Dividend yield (eoy) | % | 0.8 | 0.8 | 0.8 | 0.9 | 1.3 | |
| Book value per share (Unadj.) | Rs | 55.7 | 68.0 | 85.4 | 101.5 | 101.4 | |
| Adj. book value per share | Rs | 55.7 | 68.0 | 85.4 | 101.5 | 101.4 | |
| Shares outstanding (eoy) | m | 1,023.74 | 1,023.74 | 1,023.74 | 1,023.74 | 1,023.74 | |
| Bonus/Rights/Conversions | FV5:1 | - | - | - | - | ||
| Price / Sales ratio | x | 4.1 | 4.2 | 4.0 | 2.9 | 2.0 | |
| Avg P/E ratio | x | 19.8 | 25.8 | 25.7 | 19.9 | 23.7 | |
| P/CF ratio (eoy) | x | 17.2 | 20.7 | 19.9 | 15.1 | 15.0 | |
| Price / Book Value ratio | x | 6.8 | 5.6 | 5.4 | 3.6 | 2.8 | |
| Dividend payout | % | 16.7 | 21.6 | 19.6 | 18.9 | 29.8 | |
| Avg Mkt Cap | Rs m | 388,458 | 391,581 | 470,664 | 378,170 | 286,033 | |
| No. of employees | `000 | 15.4 | 16.9 | 11.8 | 12.4 | 13.4 | |
| Total wages/salary | Rs m | 12,616 | 15,198 | 18,545 | 21,241 | 24,145 | |
| Avg. sales/employee | Rs Th | 6,105.0 | 5,563.0 | 10,072.7 | 10,585.0 | 10,632.7 | |
| Avg. wages/employee | Rs Th | 817.0 | 901.7 | 1,569.1 | 1,707.8 | 1,801.2 | |
| Avg. net profit/employee | Rs Th | 1,272.1 | 901.5 | 1,547.7 | 1,526.5 | 898.5 | |
| CADILA HEALTHCARE INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 94,268 | 93,765 | 119,049 | 131,656 | 142,531 | |
| Other income | Rs m | 1,156 | 1,284 | 1,132 | 2,011 | 1,139 | |
| Total revenues | Rs m | 95,424 | 95,049 | 120,181 | 133,667 | 143,670 | |
| Gross profit | Rs m | 23,305 | 19,044 | 28,475 | 29,731 | 24,198 | |
| Depreciation | Rs m | 2,921 | 3,733 | 5,388 | 5,986 | 6,965 | |
| Interest | Rs m | 528 | 446 | 911 | 1,935 | 3,418 | |
| Profit before tax | Rs m | 21,012 | 16,149 | 23,308 | 23,821 | 14,954 | |
| Minority Interest | Rs m | 430 | 338 | 628 | 469 | 288 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | -25 | -3 | 0 | 0 | 0 | |
| Tax | Rs m | 1,774 | 1,289 | 5,644 | 5,303 | 3,198 | |
| Profit after tax | Rs m | 19,643 | 15,195 | 18,292 | 18,987 | 12,044 | |
| Gross profit margin | % | 24.7 | 20.3 | 23.9 | 22.6 | 17.0 | |
| Effective tax rate | % | 8.4 | 8.0 | 24.2 | 22.3 | 21.4 | |
| Net profit margin | % | 20.8 | 16.2 | 15.4 | 14.4 | 8.5 | |
| CADILA HEALTHCARE BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 42,804 | 60,223 | 82,005 | 84,981 | 87,154 | |
| Current liabilities | Rs m | 34,610 | 53,058 | 60,720 | 73,425 | 82,694 | |
| Net working cap to sales | % | 8.7 | 7.6 | 17.9 | 8.8 | 3.1 | |
| Current ratio | x | 1.2 | 1.1 | 1.4 | 1.2 | 1.1 | |
| Inventory Days | Days | 52 | 70 | 73 | 75 | 71 | |
| Debtors Days | Days | 68 | 89 | 98 | 110 | 94 | |
| Net fixed assets | Rs m | 46,987 | 72,984 | 83,703 | 133,493 | 133,236 | |
| Share capital | Rs m | 1,024 | 1,024 | 1,024 | 1,024 | 1,024 | |
| "Free" reserves | Rs m | 55,968 | 68,576 | 86,421 | 102,839 | 102,733 | |
| Net worth | Rs m | 56,992 | 69,600 | 87,445 | 103,863 | 103,757 | |
| Long term debt | Rs m | 8,964 | 24,684 | 25,551 | 39,497 | 32,146 | |
| Total assets | Rs m | 105,506 | 152,207 | 180,653 | 234,831 | 236,866 | |
| Interest coverage | x | 40.8 | 37.2 | 26.6 | 13.3 | 5.4 | |
| Debt to equity ratio | x | 0.2 | 0.4 | 0.3 | 0.4 | 0.3 | |
| Sales to assets ratio | x | 0.9 | 0.6 | 0.7 | 0.6 | 0.6 | |
| Return on assets | % | 19.1 | 10.3 | 10.6 | 8.9 | 6.5 | |
| Return on equity | % | 34.5 | 21.8 | 20.9 | 18.3 | 11.6 | |
| Return on capital | % | 33.3 | 18.0 | 22.0 | 18.3 | 13.7 | |
| Exports to sales | % | 47.2 | 0 | 0 | 0 | 0 | |
| Imports to sales | % | 6.2 | 0 | 0 | 0 | 0 | |
| Exports (fob) | Rs m | 44,537 | 0 | 0 | 0 | 0 | |
| Imports (cif) | Rs m | 5,838 | 0 | 0 | 0 | 0 | |
| Fx inflow | Rs m | 44,881 | 21,280 | 42,683 | 48,404 | 52,752 | |
| Fx outflow | Rs m | 9,069 | 10,874 | 11,242 | 11,593 | 14,504 | |
| Net fx | Rs m | 35,812 | 10,406 | 31,441 | 36,811 | 38,248 | |
| CADILA HEALTHCARE CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 18,935 | 13,117 | 9,193 | 12,819 | 25,054 | |
| From Investments | Rs m | -8,635 | -28,719 | -9,737 | -42,387 | -10,123 | |
| From Financial Activity | Rs m | -9,348 | 23,158 | 515 | 18,846 | -10,942 | |
| Net Cashflow | Rs m | 991 | 7,556 | -29 | -8,109 | 3,989 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Pankaj R. Patel (MD) | COMP SEC: Upen H. Shah | YEAR OF INC: 1995 | BSE CODE: 532321 | FV (Rs): 5 | DIV YIELD (%): 0.6 |
Read: CADILA HEALTHCARE 2019-20 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: ORCHID PHARMA LUPIN FDC SANOFI INDIA JUBILANT PHARMOVA
Compare CADILA HEALTHCARE With: ORCHID PHARMA LUPIN FDC SANOFI INDIA JUBILANT PHARMOVA
Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Ends 202 Points Lower; Britannia and Mahindra & Mahindra Among Top Nifty Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Views on news
CADILA HEALTHCARE at All Time High; BSE HEALTHCARE Index Down 0.4% (Market Updates)
Apr 23, 2021 | Updated on Apr 23, 2021CADILA HEALTHCARE share price has hit an all time high at Rs 577 (up 4.4%). The BSE HEALTHCARE Index is down by 0.4%. Among the top gainers in the BSE HEALTHCARE Index today are CADILA HEALTHCARE (up 4.4%) and PROCTER & GAMBLE HEALTH (up 0.5%). The top losers include NATCO PHARMA and IPCA LABS (down 0.1%).
CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)
Oct 26, 2020 | Updated on Oct 26, 2020Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)
Aug 21, 2020 | Updated on Aug 21, 2020For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK CADILA HEALTHCARE
- Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CADILA HEALTHCARE
CADILA HEALTHCARE - AJANTA PHARMA COMPARISON
COMPARE CADILA HEALTHCARE WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.